<a href="https://laohu8.com/S/APLM">Apollomics Inc</a>. Receives Nasdaq Delisting Notice, Will Appeal to Retain Listing Amid Ongoing Operations and New Funding
**Apollomics Inc. Faces Nasdaq Delisting, Plans to Appeal** Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company, announced it received a delisting notification from the Nasdaq Stock Market on September 18, 2025. The Nasdaq staff cited concerns that Apollomics is now only a "public shell" with no ongoing operating business, referencing a lack of personnel and uncertainty around staffing. Despite these concerns, Apollomics maintains that it is still an active pharmaceutical company and recently secured $4.1 million in new funding, appointed a new board of directors, and reversed previous plans to wind up its business. The company is continuing operations and focusing on advancing its oncology drug development programs, including the lead candidate, vebreltinib. Apollomics has announced that it will appeal the delisting decision in an effort to retain its Nasdaq listing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollomics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-217820), on September 25, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。